| Course | PHI FPX 3200 Ethics in Health Care |
|---|---|
| Assessment | Assessment 2 |
| Paper type | Policy ethics analysis |
| Length | About 1,140 words, 5 pages |
| Format | APA 7 student paper |
| School | Capella University |
| Program | Undergraduate health care core |
| Updated | September 2026 |
Free sample paper for PHI FPX 3200 Assessment 2
Too Few Doses for the Season: Allocating Nirsevimab During the 2023 Shortage, With the Groups Described by Circumstance, Three Policies Tested, and the Infants Who Pay Named
Student Name
Capella University
PHI FPX 3200: Ethics in Health Care
Instructor Name
Month Day, Year
The Constraint That Forces a Choice
In the fall of 2023, a new long-acting antibody for infants, nirsevimab, became available to protect against respiratory syncytial virus (RSV), the leading cause of hospitalization in infants in the United States. The Advisory Committee on Immunization Practices recommended one dose for all infants under 8 months entering their first RSV season, and a dose for some children aged 8 to 19 months at higher risk in their second season (Jones et al., 2023). Demand quickly exceeded supply. On October 23, 2023, the Centers for Disease Control and Prevention (2023) issued interim guidance to prioritize the limited 100 mg doses. Lake County Health Department, a composite department whose clinics cover farm towns and two small cities, received 140 doses of the 100 mg product for its public clinics in November, against an estimated 610 eligible infants weighing 5 kilograms or more who rely on those clinics. The constraint is not temporary inconvenience. RSV season peaks before more doses are promised, so some infants will go through the season unprotected no matter what the department decides.
Affected Groups Described by Circumstance
Four groups have a claim on the 140 doses. The first is infants under 6 months who weigh 5 kilograms or more, about 250 in the clinic population; they face the highest risk of hospitalization, because RSV severity falls with age. The second is infants aged 6 to 8 months with conditions such as prematurity under 29 weeks, chronic lung disease, or congenital heart disease, about 25 infants; their risk is high despite their age. The third is healthy infants aged 6 to 8 months, about 300; their risk is real but lower. The fourth is American Indian infants from the county's tribal community, about 35 across ages, whose rates of severe RSV disease are known to be higher. Families also differ in their alternatives. Some infants born after mid-September had mothers who received the maternal RSV vaccine during pregnancy and are already partly protected. Families with private pediatricians may be able to find doses elsewhere, while families who rely on the public clinic, often uninsured or covered by Medicaid, cannot.
Principles Applied at Population Scale
Justice carries the most weight at this scale. Emanuel et al. (2020) argue that when scarce medical resources must be allocated, the leading values are maximizing benefits, treating people equally, promoting and rewarding instrumental value, and giving priority to the worst off, and that no single value should decide every case. Maximizing benefit points to the youngest infants, because the dose prevents the most hospitalizations where the risk is highest. Priority to the worst off points both to the medically fragile older infants and to the tribal community, whose higher risk reflects unequal conditions, not chance. Equal treatment, such as a lottery among all 610 infants, treats every family the same but directs most doses to infants who would have done well without them. The evidence gives these values a scale. In the trial that supported approval, nirsevimab reduced medically attended RSV lower respiratory tract infection by 74.5% in healthy late-preterm and term infants (Hammitt et al., 2022). Each dose given to a high-risk infant therefore prevents more serious illness than a dose given to a low-risk infant. Justice here is not a single rule; it is a choice about which unfairness the county will accept.
Candidate Policies Tested
Policy A, first come, first served, is simple and appears neutral. It would, in practice, reward families who can take time off work to arrive early, and it ignores risk entirely. It fails on both benefit and fairness. Policy B, a lottery among all eligible infants, is equal in form and resists favoritism, but it gives about half the doses to healthy infants aged 6 to 8 months, the lowest-risk group. It sacrifices much of the benefit. Policy C follows the structure of the Centers for Disease Control and Prevention (2023) guidance: doses go first to infants under 6 months, to American Indian infants under 8 months, and to infants aged 6 to 8 months with qualifying conditions; infants whose mothers received the RSV vaccine at least 14 days before birth are not prioritized. These priority groups total about 285 infants after removing protected infants, still more than 140, so within them the department orders doses by youngest age first and holds back 15 doses for newborns expected in December. Policy C best serves benefit and priority to the worst off, and it is transparent, because the rule is public and the same for every family.
The Group That Pays, Named
Under Policy C, the families who pay are those of healthy infants aged 6 to 8 months, about 300 infants who receive no dose this season. Some of them will be hospitalized with RSV who would not have been with a dose, and the county should not pretend otherwise. The department owes these families three things: a plain explanation of the rule, advice on the steps that lower RSV risk at home, and a promise that they move first if supply improves. Some infants just short of 6 months will also be outranked by younger infants.
Evidence Limits and a Fair Process
The analysis should not claim more than the evidence supports. The trial showed a clear reduction in medically attended RSV infection, but its estimate for hospitalization was less precise, so the number of hospital stays prevented in Lake County can only be estimated. The risk groups are also broad categories, not individual scores, and some infants outside them will turn out to be at higher risk than the rule assumed. Because the rule will be imperfect, the process around it matters. The department publishes the priority order and its reasons on its website and in the clinics. A pediatrician may request an exception for an infant with a serious condition not on the list, and a nurse and the health officer review each request within two days. The order is revised as soon as more doses arrive, and the department records how many doses went to each group so the public can see the rule was followed.
Conclusion
Lake County cannot protect every infant, so it must decide who goes without. Allocating by risk, with the tribal community and fragile older infants included, prevents the most serious illness and gives priority to those whose risk is greatest, while a public rule protects fairness in process. The cost is carried by healthy older infants and their families, and naming that cost is part of making the policy just.
References
Centers for Disease Control and Prevention. (2023, October 23). Limited availability of nirsevimab in the United States: Interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023-2024 respiratory virus season (Health Alert Network Health Advisory CDCHAN-00499). https://www.cdc.gov/han/2023/han00499.html
Emanuel, E. J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., Zhang, C., Boyle, C., Smith, M., & Phillips, J. P. (2020). Fair allocation of scarce medical resources in the time of Covid-19. New England Journal of Medicine, 382(21), 2049-2055. https://doi.org/10.1056/NEJMsb2005114
Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., Wählby Hamrén, U., Mankad, V. S., Ren, P., Takas, T., Abram, M. E., Leach, A., Griffin, M. P., & Villafana, T. (2022). Nirsevimab for prevention of RSV in healthy late-preterm and term infants. New England Journal of Medicine, 386(9), 837-846. https://doi.org/10.1056/NEJMoa2110275
Jones, J. M., Fleming-Dutra, K. E., Prill, M. M., Roper, L. E., Brooks, O., Sánchez, P. J., Kotton, C. N., Mahon, B. E., Meyer, S., Long, S. S., & McMorrow, M. L. (2023). Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR. Morbidity and Mortality Weekly Report, 72(34), 920-925. https://doi.org/10.15585/mmwr.mm7234a4
The Capella PHI FPX 3200 Assessment 2 instructions
The instructions ask you to analyze the ethics of a health policy or allocation decision. You define the policy problem and the constraint, such as scarcity, identify the groups affected, apply ethical principles at the population level, such as justice, utility and priority to the worst off, compare several policy options, state who bears the cost of each and describe a fair process for deciding. Frameworks such as accountability for reasonableness support the process discussion. Evidence on the policy area, such as public health data, should be current and cited. The analysis should be honest that every allocation leaves someone worse off.
How the PHI-FPX3200 Assessment 2 example is put together
The example is organized around the distribution question. It opens by defining the policy problem and its constraint, the scarcity or barrier that makes some allocation unavoidable, because without the constraint stated the later trade-offs look optional. A stakeholder section then describes the affected groups concretely: their numbers where sources exist, their alternatives, what each stands to lose. The ethical core follows, applying the principle set at scale and showing where fairness and benefit part ways on these facts. The example then evaluates two or three candidate policies against that analysis, rather than announcing one, and argues for the option whose costs it can defend. A limitations paragraph concedes what the analysis cannot settle. The conclusion states the chosen policy, its ethical warrant, and the group that pays for it, in that order.
Where the marks sit in the PHI FPX 3200 Assessment 2 scoring guide
The scoring guide rates the problem and constraint, the affected groups, the principles, the policy comparison, the named costs and the process. The constraint reaches Distinguished when stated clearly, such as the number of doses against the number of eligible infants. Affected groups score higher when described by circumstance, such as infants in rural areas far from pediatric practices. Principles earn credit when applied at population scale rather than to one patient. The policy comparison should test each option against the principles. Naming who pays under each policy shows ethical honesty. The process criterion rewards transparency, appeals and revision as new evidence arrives.
PHI FPX 3200 Assessment 2 help from the desk
Students often analyze a policy as if it were a single patient case, missing population-level principles. Another common mistake is describing groups with labels rather than circumstances that affect access and risk. Policy options are described but not compared. Every option is presented as fair, hiding who loses. Evidence is outdated. The decision process is left out, though a fair process is central to allocation ethics. Using a specific, dated example, like the 2023 nirsevimab shortage, keeps the analysis concrete and checkable. Equity deserves explicit attention, since first-come allocation tends to favor families with easier access to pediatric care. Name the decision maker, such as a state health department or a health system committee, so the process has an owner.
Get a PHI FPX 3200 Assessment 2 example written to your instructions
Forward the Assessment 2 instructions and scoring guide from your PHI FPX 3200 courseroom, plus the policy question your section works with. We produce a custom example against those criteria, with the affected groups and trade-offs made concrete, inside 24 to 48 hours. There is no charge for the first custom sample. The paper above is an original model document written by our desk, not a submitted student paper and not an official Capella University document.
More PHI FPX 3200 papers and Undergraduate health care core samples
- PHI FPX 3200 Assessment 1: Ethical Case Analysis
- PHI FPX 3200 Assessment 3: Position Defense Paper
- BHA FPX 2002 Assessment 2: Comparative Analysis
- BHA FPX 2003 Assessment 2: Implications Analysis
- BHA FPX 2006 Assessment 2: Compliance Plan
- BHA FPX 4104 Assessment 2: Recruitment and Retention Plan
PHI FPX 3200 Assessment 2 questions, answered
What policy topics fit PHI FPX 3200 Assessment 2?
Anything where a genuine constraint forces distribution: organ allocation, staffing scarce specialties, vaccine or bed prioritization, coverage rules, mandates that trade individual choice against community protection. The topic matters less than the tension, so pick a question where two defensible values point at different policies. A topic everyone already agrees about leaves the analysis nothing to adjudicate.
How is this different from the clinical case assessment?
The reasoning discipline is the same; the unit of analysis changes. The earlier work adjudicates principles for one patient with a name and a chart, while this one weighs them across groups, which pushes justice to the front and makes distribution the central question. Reusing a bedside analysis with the word policy added typically misses the population-level criteria entirely.
Do I need data about the affected groups?
Where published figures exist and your claims lean on them, cite them; where they do not, describe the groups qualitatively and say so rather than inventing numbers. The criteria want concreteness, not fabricated precision. A clearly described group with sourced context supports an ethical argument better than a statistic that cannot be traced, and scoring guides in this course read sourcing closely.
Where can I find a free PHI FPX 3200 Assessment 2 sample paper?
This page holds the full allocation ethics analysis of the 2023 nirsevimab shortage, with the constraint, affected groups, principles, three policies and who pays. A model analysis of another policy is available free.
What is accountability for reasonableness in PHI FPX 3200 Assessment 2?
A framework by Daniels and Sabin for fair allocation decisions, requiring that reasons be public, relevant, open to appeal and revision, and enforced. It helps show a decision was made fairly even when people disagree.